GERD AND MANAGEMENT MODALITIES
DOI:
https://doi.org/10.55640/Keywords:
GERD, PPIs, PPI-refractory GERD, P-CABs, LES, esophageal motility, refractory GERD, long-term relief, quality of life, vonoprazan, tegoprazan, fexuprazanAbstract
Gastroesophageal reflux disease (GERD) is a chronic disorder resulting from the retrograde flow of gastric contents into the esophagus, leading to a spectrum of complications that adversely affect quality of life, increase morbidity, and impose substantial healthcare costs. The primary therapeutic objectives in GERD management are the alleviation of symptoms, prevention of recurrence, and promotion of mucosal healing in erosive esophagitis. First-line therapy typically consists of lifestyle modifications aimed at reducing gastric acid exposure, in conjunction with proton pump inhibitors (PPIs) to suppress acid secretion. For patients with persistent or refractory symptoms, despite optimized medical therapy, endoscopic techniques or surgical interventions such as anti-reflux procedures may provide symptomatic relief and improved disease control. This review will address the underlying pathophysiology of GERD, advances in diagnostic modalities, and contemporary therapeutic strategies, including surgical options for the management of refractory disease.
Downloads
References
1.Katz, P. O., Gerson, L. B., & Vela, M. F. (2013). Guidelines for the diagnosis and management of gastroesophageal reflux disease. The American Journal of Gastroenterology, 108(3), 308–328. (doi.org in Bing)
2.Vakil, N., van Zanten, S. V., Kahrilas, P., Dent, J., & Jones, R. (2006). The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. The American Journal of Gastroenterology, 101(8), 1900–1920. (doi.org in Bing)
3.Scarpignato, C., Gatta, L., Zullo, A., & Blandizzi, C. (2016). Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Medicine, 14(1), 179. (doi.org in Bing)
4.Ashida, K., Sakurai, Y., Nishimura, A., Kudou, K., Hiramatsu, N., & Umegaki, E. (2016). Randomised clinical trial: Efficacy and safety of vonoprazan versus lansoprazole in patients with erosive oesophagitis. Alimentary Pharmacology & Therapeutics, 43(2), 240–251. https://doi.org/10.1111/apt.13466
5.Kahrilas, P. J., & Boeckxstaens, G. (2016). Failure of reflux inhibitors in clinical trials: Lessons for future development. Journal of Neurogastroenterology and Motility, 22(4), 509–516. https://doi.org/10.5056/jnm16094
6.Shaheen, N. J., & Richter, J. E. (2009). Barrett’s esophagus. The Lancet, 373(9666), 850–861. (doi.org in Bing)
7.El-Serag, H. B., Sweet, S., Winchester, C. C., & Dent, J. (2014). Update on the epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut, 63(6), 871–880. (doi.org in Bing)
8.Gyawali, C. P., Kahrilas, P. J., Savarino, E., Zerbib, F., Mion, F., Smout, A. J., ... & Sifrim, D. (2018). Modern diagnosis of GERD: The Lyon Consensus. Gut, 67(7), 1351–1362. (doi.org in Bing)
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India